Abstract
<p>Supplementary Figures - SF1: GI50 determinations for CHK1 inhibitor SRA737 in A549 and SW620 cells. SF2: Knockdown of POLA1, POLE or POLE2 sensitises A549 and SW620 cells to the CHK1 inhibitor MK-8776. SF3: Knockdown of CHK1 sensitises A549 cells to the DNA polymerase inhibitor aphidicolin. SF4: POLA1, POLE or POLE2 knockdown is synthetically lethal with the CHK1 inhibitor SRA737 in additional NSCLC and colorectal cancer cell lines. SF5: Western blot analysis of POLA1, POLE and POLE2 knockdown in additional NSCLC cell lines. Western blot analysis of POLA1, POLE and POLE2 knockdown in additional colorectal cancer cell lines. SF7: SRA737 and gemcitabine synergistically inhibit the proliferation of 4 NSCLC cell lines. SF8: An additive interaction between SRA737 and aphidicolin in the HBEC3-KT cell line. SF9: Effect of CHK1 or B-family DNA polymerase pharmacological inhibition alone or in combination on RPA32 phosphorylation in A549 cells. SF10: Effect of CHK1 or B-family DNA polymerase pharmacological inhibition alone or in combination on �H2AX foci in A549 cells. SF 11: Correlation between POLA1, POLE and POLE2 basal protein expression in NSCLC and colorectal cancer cell lines. SF12: Lack of correlation between POLA, POLE and POLE2 basal protein expression and SRA737 or aphidicolin combination indices in NSCLC and colorectal cancer cell lines.</p>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.